City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Mihaela Cristea, MD  
Search results:  14  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-14 Trials Jump to page:

COH Protocol Number: 16151 ClinicalTrials.gov Number: NCT02345265

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-139, NCI#9825: A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

COH Protocol Number: 15147 ClinicalTrials.gov Number: NCT02194738

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

COH Protocol Number: 15146 ClinicalTrials.gov Number: NCT02193282

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15145 ClinicalTrials.gov Number: NCT02201992

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

COH Protocol Number: 15056 ClinicalTrials.gov Number: NCT02419417

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors

COH Protocol Number: 15014 ClinicalTrials.gov Number: NCT02101775

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-131, NCI#9568: A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

COH Protocol Number: 14355 ClinicalTrials.gov Number: NCT02259699

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  Ovarian Cancer Patient-Centered Decision Aid

COH Protocol Number: 14257

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  Longitudinal Urinary and Blood cfDNA EGFR Mutational Analysis

COH Protocol Number: 13373 ClinicalTrials.gov Number: NCT02275039

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  A Phase I Study of a p53MVA Vaccine in Combination with Gemcitabine in Ovarian Cancer

COH Protocol Number: 13204 ClinicalTrials.gov Number: NCT00719303

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  GOG-0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

COH Protocol Number: 12370 ClinicalTrials.gov Number: NCT01386385

Principal Investigator: Mihaela Cristea, MD
Sponsor: Cooperative Group

Title:  SWOG S1206: A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

COH Protocol Number: 12291 ClinicalTrials.gov Number: NCT01567891

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer

COH Protocol Number: 09188 ClinicalTrials.gov Number: NCT00978250

Principal Investigator: Mihaela Cristea, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-94/NCI#8351; A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd+THU)

COH Protocol Number: 07187

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  Evaluation of Ovarian Cancer and Outcomes of Care

 
Results per page: 25 50 100 All 1-14 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.